Cann Group (CAN.AX) Aktsia Kursus
Cann Group Kursus
Käive kasvas 79,5 % aastas viimase 11 aasta jooksul 8,56 M AUD-ni. Cann Group netomarginaal on nüüd 237,1 %, tõusnud −412,9 %-lt mõni aasta tagasi.
Cann Group aktsiahinnad
Hangi need andmed Eulerpool API kaudu
100 000 päringut/kuus tasuta · krediitkaarti pole
Cann Group ärimudel ja aktsia analüüs
Korduma kippuvad küsimused Cann Group aktsia kohta
Cann Group Ltd is an Australian company that operates in the medicinal cannabis industry. Its business model revolves around cultivation, manufacturing, and distribution of pharmaceutical-grade cannabis products and providing services to the medicinal cannabis sector. With a focus on research and development, Cann Group aims to support healthcare professionals and patients by developing high-quality therapeutic products derived from cannabis plants. The company's expertise lies in the production of standardized cannabis cultivars, extraction, and development of new formulations to meet the evolving needs of the medical industry. Cann Group Ltd strives to establish itself as a leading player in the medicinal cannabis market.
Cann Group Ltd is primarily active in the cannabis industry.
The main competitors of Cann Group Ltd in the market include other companies involved in the production and distribution of medical cannabis and cannabis-related products. Some significant competitors of Cann Group Ltd may include AusCann Group Holdings Ltd, Althea Group Holdings Ltd, and Little Green Pharma Ltd. These companies operate in the same industry and focus on the cultivation, manufacturing, and sale of medical cannabis products. Cann Group Ltd competes with these companies to gain market share, secure partnerships, and expand their customer base in the rapidly growing cannabis industry.
Cann Group Ltd is an Australian company that specializes in cultivating and producing medical cannabis. Established in 2014, Cann Group was the first to be granted a license to cultivate and research cannabis for medicinal purposes in Australia. With a strong commitment to quality and compliance, the company has built state-of-the-art facilities and established strategic partnerships to expand its operations. Cann Group is dedicated to providing safe and effective cannabis-based products to improve patient outcomes and is at the forefront of the rapidly growing medicinal cannabis industry in Australia.
Cann Group Ltd has achieved several significant milestones in its operations. Firstly, the company became the first Australian business to obtain a license to cultivate medicinal cannabis for research purposes in 2017. This achievement positioned Cann Group Ltd as a pioneer in the country's emerging medicinal cannabis industry. Additionally, the company successfully completed its first commercial cannabis harvest in 2018, marking another important milestone. Furthermore, Cann Group Ltd obtained its crucial Manufacture License in 2019, allowing the company to produce and distribute medicinal cannabis products in Australia. These milestones highlight Cann Group Ltd's commitment to advancing the availability and quality of medicinal cannabis within the country's market.
Cann Group Ltd is primarily present in Australia.
Cann Group Ltd, a leading Australian medicinal cannabis company, embodies a strong set of values and corporate philosophy. The company is committed to producing high-quality medical cannabis products to improve the lives of patients. Cann Group values innovation and sustainability, constantly seeking new ways to enhance their cultivation and manufacturing processes. With a focus on research and development, they aim to continually expand their product offerings and provide effective and safe treatments. Cann Group Ltd prides itself on its dedication to investors, transparency, and regulatory compliance, ensuring a trustworthy and reliable approach to business.
5 analüütikut hindavad praegu Cann Group aktsiat: 4 soovitab osta, 1 hoida ja 0 müüa.
Praeguse kursiga kaubeldakse Cann Group aktsiaga 0,00 EUR (0,00 AUD) juures.
Cann Group aktsia (CAN.AX) on noteeritud 3 börsil, sh: ASX (CAN.AX), Frankfurt (CVJ.F).
Cann Group Ltd is an Australian company specializing in the medical cannabis market. Its business model involves producing, developing, and distributing cannabis for medical use. The company serves various segments, such as the market for human medical products, the veterinary sector, and the recreational and wellness sector. The company is well positioned to benefit from the growing demand for medical cannabis, CBD products for pets, and recreational products.
Cann Group käive on 8,56 M AUD. See näitaja põhineb praegusel finantsandmetel ja peegeldab ettevõtte äritulemuseid.
Cann Group kasum on 20,30 M AUD. Netokasum peegeldab ettevõtte kasumlikkust pärast kõigi kulude mahaarvamist.
Võrdlusarvud hinna ja kasumiga (P/E) Cann Group jaoks on praegu 0,30. P/E-suhtarv võrdleb praegust aktsiahinnad kasumiga aktsia kohta ja aitab investoritel hinnata Cann Group aktsia väärtust.
Kursuse ja müügimahu suhe (P/S) Cann Group jaoks on praegu 0,71. P/S-suhtarv võrdleb börsikapitalisatsooni aastase tuluga ja teenib hindamismõõdikuna Cann Group aktsia jaoks.
Eulpooli kvaliteedinäitaja Cann Group jaoks on 3/10.
Cann Group ISIN on AU000000CAN2. ISIN (rahvusvaheline väärtpaberi identifitseerimise number) on väärtpaberite globaalne unikaalne tuvastaja.
Cann Group WKN on A2DSUQ. WKN (Wertpapierkennnummer) on kuuekohaline saksa väärtpaberi identifitseerimise number.
Cann Group ticker on CAN.AX. Ticker-sümbol kasutatakse Cann Group aktsiate kauplemiseks börsil.
Cann Group aktsia
Cann Group konkurendid
Cann Group Börsiticker
Cann Group FIGI
Kõik teised näitajad ja analüüsid Cann Group kohta sügavamalt
Meie Cann Group-aktsia analüüs sisaldab olulisi finantsnäitajaid, nagu käive, kasum, P/E suhe, P/S suhe, EBIT, samuti teavet dividendi kohta. Lisaks käsitleme aspekte nagu aktsiad, turukapitalisatsioon, võlad, omakapital ja kohustused ettevõttes Cann Group. Kui otsite nende teemade kohta põhjalikumat teavet, pakume teile meie alamlehtedel üksikasjalikke analüüse: